Media Center
Press Releases

Press Releases

17 Oct 17
Industry pipeline for monoclonal antibodies encompasses over 2,800 programs, says GBI Research

The overall industry pipeline for monoclonal antibodies (mAbs) has reached a unprecedented scale now accounting for almost 3,000 distinct pipeline programs across a range of therapy areas, according to business intelligence provider GBI Research.

Read post
13 Oct 17
New Diabetes Therapeutics to Steal Ground from Insulin Therapies, says GBI Research

The incidence of diabetes mellitus (DM), and most notably type 2 diabetes mellitus (T2DM), which accounts for 90–95% of all DM cases, is growing rapidly on a global scale, according to business intelligence provider GBI Research.

Read post
09 Oct 17
Type 2 diabetes market in South-East Asia is set to experience strong growth to hit $2.9 billion by 2023, says GBI Research

The South-East Asian Type 2 Diabetes Mellitus (T2DM) market, which includes South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam and Indonesia, will rise from $1.92 billion in 2016 to $2.96 billion by 2023, at a Compound Annual Growth Rate (CARG) of 6.3%, according to business intelligence provider GBI Research.

Read post
26 Sep 17
Global Respiratory Market to be Worth $41.3 billion by 2023, says GBI Research

The global marketplace for respiratory diseases across the seven major pharmaceutical markets *(7MM) is projected to exceed $41.3 billion in sales by 2023, at a compound annual growth rate (CAGR) of 4.2% from 2016–2023, according to business intelligence provider GBI Research.

Read post
25 Sep 17
Successor to PD-1 inhibitors the focus of cancer immunotherapy development, says GBI Research

The cancer immunotherapies pipeline, which comprises of 3,100 products and encompasses over a third of all products in development for oncology, displays a high level of first-in-class innovation with novel developments focusing heavily on producing the next big immune checkpoint inhibitor, according to business intelligence provider GBI Research.

Read post